Hangzhou Diagens Biotechnology Co., Ltd. (HKG:2526)
Hong Kong · Delayed Price · Currency is HKD 526.00
+104.20 (24.70%)
Aug 21, 2026, 4:08 PM HKT
HKG:2526 Revenue
Hangzhou Diagens Biotechnology had revenue of 54.35M CNY in the quarter ending June 30, 2026, with 21.03% growth. This brings the company's revenue in the last twelve months to 183.31M. In the year 2025, Hangzhou Diagens Biotechnology had annual revenue of 164.42M with 133.72% growth.
Revenue (ttm)
183.31M CNY
Revenue Growth
+133.72%
P/S Ratio
220.91
Revenue / Employee
1.05M CNY
Employees
174
Market Cap
46.75B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 164.42M | 94.07M | 133.72% |
| Dec 31, 2024 | 70.35M | 17.51M | 33.13% |
| Dec 31, 2023 | 52.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.